Schaper Benz & Wise Investment Counsel Inc. WI Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Schaper Benz & Wise Investment Counsel Inc. WI lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,334 shares of the biopharmaceutical company’s stock after buying an additional 1,220 shares during the period. Schaper Benz & Wise Investment Counsel Inc. WI’s holdings in Regeneron Pharmaceuticals were worth $13,772,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Personal CFO Solutions LLC increased its holdings in shares of Regeneron Pharmaceuticals by 230.1% in the fourth quarter. Personal CFO Solutions LLC now owns 1,852 shares of the biopharmaceutical company’s stock worth $1,319,000 after buying an additional 1,291 shares during the period. Atlantic Union Bankshares Corp increased its holdings in Regeneron Pharmaceuticals by 76.3% during the 4th quarter. Atlantic Union Bankshares Corp now owns 3,996 shares of the biopharmaceutical company’s stock valued at $2,846,000 after purchasing an additional 1,729 shares during the period. Amundi increased its holdings in Regeneron Pharmaceuticals by 45.8% during the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock valued at $1,138,074,000 after purchasing an additional 487,489 shares during the period. Larson Financial Group LLC increased its holdings in Regeneron Pharmaceuticals by 62.0% during the 4th quarter. Larson Financial Group LLC now owns 81 shares of the biopharmaceutical company’s stock valued at $58,000 after purchasing an additional 31 shares during the period. Finally, Lifeworks Advisors LLC increased its holdings in Regeneron Pharmaceuticals by 31.5% during the 4th quarter. Lifeworks Advisors LLC now owns 6,743 shares of the biopharmaceutical company’s stock valued at $4,803,000 after purchasing an additional 1,617 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on REGN shares. Robert W. Baird reduced their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a report on Wednesday, February 5th. Wells Fargo & Company reduced their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Citigroup reduced their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Bank of America reiterated an “underperform” rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Finally, Wolfe Research began coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 target price on the stock. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $707.51 on Friday. The stock has a market capitalization of $77.35 billion, a PE ratio of 18.48, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a 12-month low of $642.00 and a 12-month high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The stock’s 50 day simple moving average is $696.12 and its 200 day simple moving average is $851.05.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm posted $11.86 EPS. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.50%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.